2Q EARNINGS: Valeant dives on lower guidance; Allergan deal value takes a hit
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals closed down 6.7% at $117.39 per share on 31 July after the Canadian specialty pharma company lowered its full-year 2014 revenue and earnings guidance despite an 86% year-over-year increase in second quarter sales to $2bn and a 43% jump in adjusted income to $651m or $1.91 per share.
You may also be interested in...
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.